In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.

The rating is put together annually by Extel, a British company that studies the global investment climate.